SNAP-8 Research Guide — Acetyl Octapeptide-3 (UK 10mg)

Research Use Only. All OL Research products are supplied strictly for in-vitro and laboratory research purposes. They are not medicines, food supplements, or cosmetic ingredients. Not for human or veterinary use. This article is written for educational and scientific reference only.

What is SNAP-8?

SNAP-8, also known by its INCI name Acetyl Octapeptide-3, is a synthetic octapeptide that mimics the N-terminal region of SNAP-25 (synaptosomal-associated protein, 25 kDa). Its sequence is Ac-EEMQRRAD (acetylated Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp), and it has a molecular weight of approximately 1076 Da. SNAP-8 was developed as an extended version of Argireline (Acetyl Hexapeptide-3), the acetylated hexapeptide sharing the first six residues of SNAP-8’s sequence, with two additional amino acids added to enhance biological activity.

Research interest in SNAP-8 stems from its proposed ability to interfere with SNARE complex assembly at the neuromuscular junction — the molecular machinery responsible for acetylcholine vesicle fusion and neurotransmitter release.

The SNARE Complex and Neurotransmitter Release

The SNARE (soluble NSF attachment protein receptor) complex is the core molecular machine mediating membrane fusion in eukaryotic cells. At the neuromuscular junction, three SNARE proteins assemble into a four-helix bundle that drives synaptic vesicle fusion with the presynaptic membrane, releasing neurotransmitters into the synaptic cleft:

SNAP-25 — a synaptosomal-associated protein contributing two helices to the complex; anchored to the presynaptic membrane
Syntaxin-1 — a single-span transmembrane protein in the presynaptic membrane
VAMP/Synaptobrevin — a vesicle-anchored protein contributing one helix

The assembly of these three proteins into the coiled-coil SNARE complex provides the energy for membrane fusion. SNAP-25 is the target of botulinum neurotoxin serotypes A and E, which cleave SNAP-25 at specific sites and thereby block neurotransmitter release — the basis for both the toxin’s lethality and its therapeutic applications in medicine.

Mechanism of SNAP-8: SNAP-25 N-Terminal Mimicry

SNAP-8 is designed to compete with endogenous SNAP-25 for binding to the SNARE complex assembly sites. By presenting a sequence identical to the N-terminal portion of SNAP-25, SNAP-8 acts as a competitive inhibitor of SNARE complex formation — reducing, but not abolishing, the efficiency of vesicle fusion and acetylcholine release at the neuromuscular junction.

This mechanism is fundamentally different from botulinum toxin, which causes irreversible proteolytic cleavage of SNAP-25. SNAP-8 instead offers reversible, competitive interference with SNARE assembly. The kinetics of this competitive inhibition — including the affinity of SNAP-8 for SNARE complex binding sites, its IC50 values in vesicle fusion assays, and its in-vitro potency relative to SNAP-25 itself and to Argireline — are active areas of characterisation in cell biology research.

In Vitro Models for Studying SNARE Inhibition

Research on SNAP-8 uses several established experimental systems. Liposome-based SNARE-mediated fusion assays use fluorescently labelled lipid vesicles bearing SNARE proteins to quantify fusion efficiency in the presence of different concentrations of SNAP-8. These assays (based on Fluorescence Resonance Energy Transfer, FRET, between donor-labelled and acceptor-labelled vesicle populations) allow quantitative measurement of fusion rate and extent, enabling IC50 determination.

PC12 cells — a well-characterised neuroendocrine cell line derived from rat phaeochromocytoma — are used to investigate catecholamine secretion as a proxy for regulated vesicle exocytosis. SNAP-25 and the other SNARE components are endogenously expressed in PC12 cells, making them an accessible model for studying SNARE-mediated secretion and its pharmacological modulation.

Skin Biology and Dermal Research Applications

The relationship between neuromuscular junction biology and skin research lies in the expression of SNARE complex components — including SNAP-25 — by non-neuronal cell types including skin keratinocytes and dermal fibroblasts. These cells engage in regulated secretion of growth factors, matrix metalloproteinases, and other bioactive mediators through vesicular pathways that involve SNARE proteins. Research into SNAP-8’s effects on keratinocyte and fibroblast secretory activity uses cytokine profiling, gelatin zymography (for MMP activity), and cell viability assays.

The expression of acetylcholine and its receptors in the skin constitutes a non-neuronal cholinergic system that regulates proliferation, differentiation, and apoptosis in keratinocytes. Research investigating the interplay between this cutaneous cholinergic system and SNARE-mediated vesicle fusion provides a mechanistic rationale for studying SNAP-8 in dermal biology contexts.

Researchers exploring the skin biology of other peptides may also wish to review our Copper Peptides research guide, which covers GHK-Cu and AHK-Cu and their roles in extracellular matrix biology and wound biology research.

Comparison with Argireline (Acetyl Hexapeptide-3)

Argireline shares the first six residues of SNAP-8 (Ac-EEMQRR). SNAP-8 extends this by two additional amino acids (Ala-Asp), which are proposed to provide additional SNARE binding contacts and improve competitive inhibition. Head-to-head comparison studies in vesicle fusion assays and cell-based secretion models allow the relative potency of these two peptides to be quantified. The question of whether the additional residues in SNAP-8 provide a meaningful enhancement in biological activity relative to Argireline at comparable concentrations remains an empirically open question in the literature, and is an area where well-designed in-vitro comparative studies can make useful contributions.

SNAP-8 Peptide Research Guide — Octapeptide, SNARE Complex and Neuromuscular Biology